Literature DB >> 11001528

Defining CD95 as a tumor suppressor gene.

M Müschen1, U Warskulat, M W Beckmann.   

Abstract

The CD95 (Apo-1/Fas) receptor-ligand system is one of the key regulators of apoptosis and is particularly important for the maintenance of lymphocyte homeostasis. There is now broad evidence that susceptibility of tumor cells towards CD95-mediated apoptosis is largely reduced. In the human, germline and somatic mutations of the CD95 gene are associated with a high risk of both lymphoid and solid tumors. Based on these observations a new concept defining CD95 as a tumor suppressor gene is discussed. In addition to CD95, its natural ligand (CD95L) is also implicated in malignant progression. Compared to their nonmalignant counterparts, malignant cells frequently exhibit aberrant de novo expression of CD95L and are able to induce CD95L-mediated apoptosis in bystander cells. The role for neoplastic CD95L expression in local tissue destruction, invasion, and metastatic spread has been established for many tumor types. CD95L expression by malignant cells may counteract the host's antitumor immunity and favors immune escape of the tumor. On this basis, the significance of loss of CD95 and gain of CD95L expression for tumor progression is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001528     DOI: 10.1007/s001090000112

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  37 in total

1.  Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.

Authors:  Lijun Shen; Anthony C T Liang; Liwei Lu; Wing Yan Au; Yok-Lam Kwong; Raymond H S Liang; Gopesh Srivastava
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

3.  FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

4.  FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report.

Authors:  Parinda A Mehta; Robert B Gerbing; Todd A Alonzo; James S Elliott; Tiffany A Zamzow; Michelle Combs; Emily Stover; Julie A Ross; John P Perentesis; Soheil Meschinchi; Beverly J Lange; Stella M Davies
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 5.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

6.  FAS-1377 A/G polymorphism in breast cancer: a meta-analysis.

Authors:  Jing Zeng; Yi Fang; Peiyu Li
Journal:  Tumour Biol       Date:  2013-11-02

Review 7.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

8.  Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis.

Authors:  Behnaz Valibeigi; Zahra Amirghofran; Hossein Golmoghaddam; Reza Hajihosseini; Fatemeh M Kamazani
Journal:  Pathol Oncol Res       Date:  2013-11-12       Impact factor: 3.201

9.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

Review 10.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.